You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

287 Results
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
CISplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
methotrexate,
leucovorin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ponatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Nivolumab - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOXOrubicin,
vinBLAStine,
dacarbazine,
nivolumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Blinatumomab - Front-line Consolidation for B-cell Precursor Acute Lymphoblastic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
blinatumomab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
gemcitabine,
oxaliplatin,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
riTUXimab (Unfunded),
polatuzumab vedotin (Unfunded),
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOXOrubicin,
cyclophosphamide,
prednisone,
brentuximab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)
ODB - General Benefit
    etoposide - oral capsules
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
cyclophosphamide,
etoposide,
brentuximab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Rectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Drugs Used:
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Jan 2026
Regimen
Cancer Type:
Gastrointestinal, 
Rectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
pemetrexed,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026

Pages